Justin Stebbing

Department of Surgery and Cancer

Imperial College London

Justin Stebbing

Professor Justin Stebbing trained in medicine at Trinity College, University of Oxford. After completion of junior doctor posts in Oxford, he undertook training and a residency at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology at The Royal Marsden and St Bartholomew's Hospitals and now through Imperial College and the aligned Imperial College Healthcare NHS Trust.

Dr Stebbing has published over 550 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing for national newspapers and presenting new data on optimal cancer therapies at major international conferences. His focus at Imperial College is on new therapies in cancer, and the systemic management of patients with solid malignancies. His laboratory work is concentrated on new druggable target discovery.

He is a Fellow of the Royal College of Physicians, the Royal College of Pathologists, and sits on the advisory Boards of a number of international cancer committees. Justin's team published in Nature Medicine, outlining the groundbreaking discovery of a new cancer-causing gene new mechanisms of cancer drug resistance. He was appointed the government's first oncology professor funded by the National Institute for Health Research (NIHR) – the mechanism the government uses to fund research through the NHS. In 2016, Professor Stebbing was internationally recognised with his appointment as co-Editor-in-Chief of Oncogene (Nature Publishing Group's cancer journal) and election to the American Society for Clinical Investigation.